Lonza has been building the science to support its ResistAid product, which is derived from larch bark. A 2016 review of data from clinical trials looking at both infection and responses to vaccinations indicated that arabinogalactan from North American Larix species (Larix laricina and Larix occidentalis) could benefit immune health in humans.
“Therefore, these results suggest a role for larch arabinogalactan in the improvement of immune system and defense against pathogens in humans,” wrote the authors in Nutrition & Metabolism.
“It is interesting to note that both models (infection and vaccine) are considered relevant by the European Food Safety Authority (EFSA) to substantiate health claims on immune system in the frame of European regulation (EC) 1924/2006 on nutrition and health claims.”
Data from one human clinical study examining the incidence of cold episodes found that Lonza’s ResistAid product could reduce cold episodes by 23%, compared to placebo (Current Medical Research and Opinion, 2013, Vol. 29, pp. 251-258).
Data from human studies using Streptococcus pneumoniae and tetanus vaccinations indicated that serum antigen-specific IgG and IgE responses improved, suggesting an immunostimulatory effect.